Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

Michael Launspach; Dennis Temel; Emily Ohlendorf; Felix Zirngibl; Bianca Materne; Lena Oevermann; Hedwig E Deubzer; Anton G Henssen; Annette Künkele; Patrick Hundsdörfer; Horst von Bernuth; Axel Pruß; Angelika Eggert; Arend von Stackelberg; Peter Lang; Johannes H Schulte

doi:10.3324/haematol.2022.281134

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

Haematologica. 2023 Jan 1;108(1):267-272. doi: 10.3324/haematol.2022.281134.

Authors

Michael Launspach¹, Dennis Temel², Emily Ohlendorf³, Felix Zirngibl³, Bianca Materne⁴, Lena Oevermann³, Hedwig E Deubzer⁵, Anton G Henssen⁶, Annette Künkele⁵, Patrick Hundsdörfer⁷, Horst von Bernuth⁸, Axel Pruß⁹, Angelika Eggert⁵, Arend von Stackelberg³, Peter Lang¹⁰, Johannes H Schulte⁵

Affiliations

¹ Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg. michael.launspach@charite.de.
² Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin.
³ Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin.
⁴ Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin.
⁵ Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg.
⁶ Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg, Germany; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin.
⁷ Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Pediatrics, Helios Klinikum Berlin-Buch, Berlin.
⁸ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; Deparment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; Labor Berlin - Charité Vivantes GmbH, Department of Immunology, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin.
⁹ Institute of Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin.
¹⁰ Department of Hematology/Oncology and General Pediatrics, Children's University Hospital, University of Tuebingen, Tuebingen.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Child
Cohort Studies
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Retrospective Studies
Risk Factors
Rituximab / adverse effects
Transplantation, Autologous

Substances

Rituximab

Grants and funding

Funding: ML is participant in the BIH Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin & the Berlin Institute of Health (BIH). HED and AK are participants in the BIH Charité Advanced Clinician Scientist Pilot program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH).